# MabSpace Biosciences Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mabspace-biosciences-co

- Industry: Healthcare
- Headquarters: Suzhou, China
- Website: www.mabspacebio.com
- Total disclosed funding: $55M
- Latest round: Series B (May 8, 2018)
- Investors on record: 3

## About

Founded in 2013 and based in Suzhou, China, MabSpace Biosciences Co., Ltd. is a biotechnology company that focuses on the development of antibody drugs and diagnostic reagents. In 2019, The company was merged with a biopharmaceutical company Transcenta Holding Ltd. The company became subsidiary brand of Transcenta Holding Ltd.

The company provides antibody-based therapeutics for the treatment of cancer and fibrotic disorders affecting lung, kidney and liver. The company uses immune tolerance breaking technology (IMBT) in generating antibodies.

## Funding rounds

- Series B, May 8, 2018, $40M — Hong Shan, Lilly Asia Ventures, King Star Capital
- Series A, Oct 29, 2015, $15M — Lilly Asia Ventures

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Hong Shan — Series B
- King Star Capital — Series B